Atossa Therapeutics (ATOS) Receivables - Net (2011 - 2017)

Atossa Therapeutics (ATOS) posted quarterly Receivables - Net of $4040.0 for Q3 2017, down 99.62% quarter-over-quarter from $1.1 million in Q3 2015.

Atossa Therapeutics (ATOS) Receivables - Net (2011 - 2017) Analysis & Trends

Atossa Therapeutics (ATOS) has reported Receivables - Net for 6 consecutive years, with $4040.0 the latest figure, recorded in Q3 2017.

In Q3 2017, Receivables - Net changed N/A year-over-year to $4040.0; the TTM figure through Sep 2017 stood at $4040.0 (changed N/A YoY), while the FY2014 annual figure was $297958.0, up 114.25% from the prior year.
Receivables - Net retreated to $4040.0 in Q3 2017 per ATOS's latest filing, from $1.1 million in the prior quarter.
Across five years, Receivables - Net topped out at $2.0 million in Q2 2015 and bottomed at $4040.0 in Q3 2017.
Historically, Receivables - Net has averaged $503026.2 across 4 years, with a median of $278648.5 in 2013.
Annual changes were most pronounced in 2014 — Receivables - Net tumbled 90.75% — and 2015, when it jumped 4078.49%.
Atossa Therapeutics' Receivables - Net stood at $139072.0 in 2013, then surged by 114.25% to $297958.0 in 2014, then soared by 254.1% to $1.1 million in 2015, then plunged by 99.62% to $4040.0 in 2017.
Business Quant data shows ATOS's Receivables - Net at $4040.0 in Q3 2017, $1.1 million in Q3 2015, and $2.0 million in Q2 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Atossa Therapeutics	22.63 Mn	22.63 Mn	-

Download Data